Physician profile
Michael A Biederman
NPI 1962472423
$8,907.37
in general payments reported to CMS, 2019-2025
31 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,121 · 2020: $1,228 · 2021: $2,223 · 2022: $1,757 · 2023: $653 · 2024: $663 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,578.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,682.27 | 2019-2025 | Linzess |
| Gilead Sciences, INC. | $1,092.01 | 2019-2025 | Livdelzi, Epclusa |
| Janssen Biotech, INC. | $909.54 | 2019-2024 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $697.32 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $577.92 | 2019-2023 | Entyvio |
| Janssen Scientific Affairs, LLC | $414.20 | 2020-2024 | Tremfya |
| Intercept Pharmaceuticals, INC. | $351.22 | 2019-2022 | |
| Pfizer INC. | $280.49 | 2019-2022 | |
| Qol Medical, LLC | $245.04 | 2019-2024 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $239.65 | 2021 | |
| Ironwood Pharmaceuticals, INC | $218.12 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $183.27 | 2020-2022 | |
| Celgene Corporation | $136.04 | 2021-2022 | |
| Medtronic, INC. | $128.90 | 2023 | Gi Genius |
| Genzyme Corporation | $126.00 | 2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $103.45 | 2023 | Gimoti |
| Boston Scientific Corporation | $98.48 | 2022 | |
| Daiichi Sankyo INC. | $86.74 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $69.46 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $43.16 | 2022 | |
| Shire North American Group INC | $38.26 | 2019 | |
| Ucb, INC. | $27.23 | 2019 | |
| Vivus LLC | $24.16 | 2022 | |
| Concordia Pharmaceuticals INC. | $22.75 | 2019 | |
| Exact Sciences Corporation | $20.01 | 2023 | Cologuard Collection Kit |
| Ardelyx, INC. | $19.01 | 2024 | Ibsrela |
| Redhill Biopharma INC. | $16.24 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.52 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.51 | 2021 | |
| Ethicon US, LLC | $12.94 | 2022 | |
| Braintree Laboratories, INC. | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Biederman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.